Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its peers.

Great things are happening to the stocks in this article. They’re all outperforming the market over the last month because of positive catalysts such as a new product line, constructive news flow, or even a loyal Reddit fanbase.

Corcept Therapeutics stock has delivered a very strong run over the past few years, yet its low overall value score suggests the current share price may already reflect a lot of optimism. After such a move, investors are weighing whether the recent gains leave enough valuation support if expectations change. Corcept Therapeutics has returned about 4.4x over the past 5 years, which puts recent pricing under closer scrutiny for signs of over enthusiasm. Recent progress in its oncology and...

Corcept Therapeutics (CORT) demonstrates exceptional price momentum with shares up more than 50% over the past year. CORT’s fundamentals are robust with revenue and earnings both projected to grow this year. Technical indicators remain bullish with a 100% “Buy” opinion from Barchart. Analyst sentiment is mixed —ratings range from “Strong...

This popular small-cap fund is trading at a premium to its own history, forcing a hard look at whether the growth inside is enough to justify the price.

Corcept Therapeutics and Anika Therapeutics received Wall Street support after reporting strong second-quarter results and sharply raising their full-year 2026 outlook.

Corcept tops Q2 earnings estimates as Korlym growth and a strong Lifyorli launch lift revenues, prompting a higher 2026 top-line outlook.

Revenue surged 32% to $256.1 million, driven by strong Cushing's syndrome sales and a successful Lifyorli launch, as the company raises full-year guidance.

Corcept (CORT) delivered earnings and revenue surprises of +1,000.00% and +18.38%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Corcept Therapeutics (NASDAQ:CORT) reported second-quarter 2026 revenue of $256.1 million, up 32% from the prior-year period, as sales from its Cushing’s syndrome franchise increased and its newly launched ovarian cancer therapy LIFYORLI contributed $47.6 million in its first quarter of availability

Biopharma company Corcept Therapeutics (NASDAQ:CORT) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 31.7% year on year to $256.1 million. The company’s full-year revenue guidance of $1.15 billion at the midpoint came in 15.1% above analysts’ estimates. Its GAAP profit of $0.36 per share was significantly above analysts’ consensus estimates.

Let’s dig into the relative performance of Corcept (NASDAQ:CORT) and its peers as we unravel the now-completed Q1 branded pharmaceuticals earnings season.

Biopharma company Corcept Therapeutics (NASDAQ:CORT) will be announcing earnings results this Wednesday after market hours. Here’s what to expect.

Shares of biopharma company Corcept Therapeutics (NASDAQ:CORT) fell 2.9% in the morning session after Wolfe Research downgraded the stock to 'Underperform' from 'Peerperform', citing valuation concerns.

Corcept Therapeutics (CORT) has attracted fresh attention after a sharp improvement in its earnings outlook, with full year earnings estimates rising significantly and analyst sentiment turning more constructive toward the stock. See our latest analysis for Corcept Therapeutics. Corcept Therapeutics' share price has climbed over recent months, with a 16.9% 1 month share price return and a 107.0% 3 month share price return, while the 5 year total shareholder return of 359.1% reflects a strong...

Recently, Corcept Therapeutics received an upgraded Zacks Rank of #2 (Buy) after analysts sharply raised their full-year earnings estimates, reflecting a much stronger profit outlook than previously expected. This improved earnings view has come alongside performance that has far outstripped the broader Medical sector and the Medical – Drugs industry, underlining how quickly sentiment can shift when projections change. We’ll now examine how this strengthened earnings outlook and analyst...

Here is how Corcept Therapeutics (CORT) and Quest Diagnostics (DGX) have performed compared to their sector so far this year.

Atabak exercised options and immediately liquidated shares under a pre-established Rule 10b5-1 trading plan adopted in December 2025.

This sale was executed under a Rule 10b5-1 trading plan adopted in March, while the stock has gained 25% over the past year.